Australia markets open in 2 hours 39 minutes
  • ALL ORDS

    7,717.10
    -80.40 (-1.03%)
     
  • AUD/USD

    0.7210
    -0.0071 (-0.98%)
     
  • ASX 200

    7,393.90
    -80.50 (-1.08%)
     
  • OIL

    84.27
    +2.15 (+2.62%)
     
  • GOLD

    1,817.30
    -4.10 (-0.23%)
     
  • BTC-AUD

    59,511.80
    -1,232.50 (-2.03%)
     
  • CMC Crypto 200

    1,037.76
    +12.03 (+1.17%)
     

Polymyositis Pipeline to Progress with New and Emerging Drugs for Treatment, Analyzes DelveInsight

·7-min read

Growing cases of chronic muscle inflammation, continuous advancement in technology and increased injuries of muscles are a few of the factors contributing to extensive research and development in the Polymyositis space. Although no permanent cure for Polymyositis is found till date, treatment therapies can improve muscle strength and function.

Las Vegas, USAPolymyositis Pipeline to Progress with New and Emerging Drugs for Treatment, Analyzes , Dec. 08, 2021 (GLOBE NEWSWIRE) -- DelveInsight’s Polymyositis Pipeline Insight 2021’ report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the Polymyositis pipeline domain.

Some of the essential takeaways from the Polymyositis Pipeline report:

  • DelveInsight’s Polymyositis Pipeline analysis depicts a robust space with 7+ active players working to develop 7+ pipeline treatment therapies.

  • Some of the key pharmaceutical companies working to develop potential drug candidates to improve the Polymyositis treatment scenario include Cytodyn, ImmunoForge, Viela Bio, Paean Biotechnology, Kezar Life Sciences Inc, Bristol-Myers Squibb, Janssen Pharmaceutical, Restem LLC and many others.

  • Essential Polymyositis pipeline therapies such as Research programme polymyositis, PF1801, VIB7734, PN-101, KZR-616, Abatacept, Ustekinumab, Umbilical Cord Lining Stem Cells and others are under development in different phases of clinical trials.

  • KZR-616 is a novel, first-in-class, selective immunoproteasome inhibitor with broad therapeutic potential across multiple autoimmune diseases developed by Kezar Life Sciences Inc. KZR-616 offers a novel approach to harmonizing the immune system via selective immunoproteasome inhibition.

  • Bristol-Myers Squibb is currently recruiting adults with active dermatomyositis or polymyositis for a clinical trial. The goal is to evaluate the effectiveness and safety of a study drug, called abatacept, in combination with standard medicines in improving symptoms of active myositis.

  • In September 2021, the US FDA granted Orphan Drug designation to PF1801 for the treatment of polymyositis.

  • In October 2020, the US FDA granted Orphan Drug Designations (ODD) for KZR-616 for the treatment of polymyositis (PM) and dermatomyositis (DM).

  • Cytodyn is conducting preclinical studies in several autoimmune diseases including polymyositis, IBS (inflammatory bowel disease), MS (Multiple Sclerosis).

  • VIB7734 is a humanized mAb intended to be a novel treatment for autoimmune diseases where the pathology is driven principally by overproduction of type I interferons and other cytokines secreted by pDCs. VIB7734 was studied in a Phase I clinical trial and the trial demonstrated that VIB7734 was generally well-tolerated and reduced pDC levels.

Request a sample and discover more about the report offerings @ Polymyositis Emerging Therapies

The Polymyositis pipeline report lays down detailed profiles of the pipeline assets, comparative analysis of clinical and non-clinical stage Polymyositis products, inactive and dormant assets, comprehensive assessment of driving and restraining factors, as well as the opportunities and risks in the Polymyositis pipeline landscape.

Polymyositis Overview

Polymyositis is a type of inflammatory myopathy, which refers to a group of muscle diseases characterized by chronic muscle inflammation and weakness. Polymyositis (PM), an autoimmune disorder, develops due to abnormal activation of cytotoxic T lymphocytes (CD8 cells) and macrophages against muscular antigens as well as the strong extrafusal muscular expression of major histocompatibility complex 1 causing damage to the endomysium of skeletal muscles. Polymyositis develops gradually over time, and it rarely affects persons younger than age 18.

Find out more about the disease and recent developments @ Polymyositis Pipeline Assessment

Polymyositis Pipeline Drugs

Drug

Company

Phase

MoA

RoA

Research programme polymyositis

Cytodyn

Preclinical

NA

NA

PF1801

ImmunoForge

Phase I

Glucagon like peptide 1 receptor agonists

NA

VIB7734

Viela Bio

Phase I

Dendritic cell inhibitors

Subcutaneous

KZR-616

Kezar Life Sciences Inc

Phase II

Proteasome inhibitors

Subcutaneous

PN-101

Paean Biotechnology

Phase I/II

Mitochondria replacements

Intravenous

Umbilical Cord Lining Stem Cells

Restem LLC

Phase I

Cell replacements

Intravenous

Abatacept

Bristol Myers Squibb

Phase III

T cell activation inhibitors

Subcutaneous

Learn more about the novel and emerging Polymyositis pipeline therapies @ Polymyositis Pipeline Analysis

Polymyositis Therapeutics Assessment

The Polymyositis Pipeline report proffers an integral view of the Polymyositis emerging novel therapies segmented by Stage, Product Type, Molecule Type, Mechanism of Action and Route of Administration.

By Product Type

  • Mono

  • Combination

  • Mono/Combination

By Stage

  • Discovery

  • Pre-clinical

  • Phase I

  • Phase II

  • Phase III

  • Pre-registration

  • Inactive candidates

By Route of Administration

  • Oral

  • Intravenous

  • Subcutaneous

By Molecule Type

  • Gene therapy

  • Stem cell therapy

  • Small molecules

  • Recombinant protein

By Mechanism of Action

  • T cell activation inhibitors

  • Cell replacements

  • Mitochondria replacements

  • Glucagon like peptide 1 receptor agonists

  • Dendritic cell inhibitors

Scope of the Polymyositis Pipeline Report

  • Coverage: Global

  • Major Players: Cytodyn, ImmunoForge, Viela Bio, Paean Biotechnology, Kezar Life Sciences Inc, Bristol-Myers Squibb, Janssen Pharmaceutical, Restem LLC and many others.

  • Key Polymyositis Pipeline Therapies: Research programme polymyositis, PF1801, VIB7734, PN-101, KZR-616, Abatacept, Ustekinumab, Umbilical Cord Lining Stem Cells, and many others.

Dive deep into rich insights for emerging therapies and assessment, visit @ Polymyositis Emerging Therapies

Table of Contents

1

Introduction

2

Executive Summary

3

Polymyositis: Overview

4

Pipeline Therapeutics

5

Late Stage Products (Phase III)

5.1

Abatacept; Bristol Myers Squibb

6

Late Stage Products (Phase III)

7

Mid Stage Products (Phase II)

7.1

KZR-616: Kezar Life sciences

8

Early Stage Products (Phase I)

8.1

PF1801: Immunoforge

9

Early Stage Products (Phase I)

10

Preclinical Stage Products

11

Therapeutic Assessment

12

Inactive Products

13

Collaborations Assessment- Licensing / Partnering / Funding

14

Polymyositis- Unmet Needs

15

Polymyositis- Market Drivers and Barriers

16

Appendix

17

About DelveInsight

For further information on the Polymyositis current pipeline therapeutics, reach out @ Polymyositis Ongoing Clinical Trials

Track and assess a candidate’s clinical development journey through Actionable Intelligence and Comparative Therapeutic Assessment

Related Reports

Polymyalgia Rheumatica Market

DelveInsight’s ‘Polymyalgia Rheumatica (PMR)–Market Insights, Epidemiology, and Market Forecast—2030’ report deliver an in-depth understanding of the Polymyalgia Rheumatica (PMR), historical and forecasted epidemiology as well as the market trends, market drivers, market barriers, and key companies involved such as Roche Chugai, Bristol-Myers Squibb, Eli Lilly, and others.

Spinal Cord Injury Market

DelveInsight’s ‘Spinal Cord Injury–Market Insights, Epidemiology, and Market Forecast - 2030’ report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology as well as the market trends, market drivers, market barriers, and key companies involved such as StemCyte, Lineage Cell Therapeutics, Kringle Pharma, AbbVie, Nipro Corporation, ReNetX Bio, Neurofix, and others.

Sarcopenia Market

DelveInsight’s ‘Sarcopenia–Market Insights, Epidemiology, and Market Forecast-2030’ report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology as well as the market trends, market drivers, market barriers and key companies involved such as Biophytis, Novartis, Eli Lily, Immunoforge, Regeneron Pharmaceuticals, Sanofi, and others.

Thrombocytopenia Market
DelveInsight’s ‘Thrombocytopenia —Market Insights, Epidemiology, and Market Forecast–2030’ report deliver an in-depth understanding of the Thrombocytopenia, historical and forecasted epidemiology as well as the Thrombocytopenia market trends, market drivers, market barriers, and key companies involved such as Sanofi (Ablynx), Rigel Pharmaceuticals, Kissei Pharmaceutical, UCB Biopharma, Principia Biopharma, and others.

Tendinopathy Market

DelveInsight’s ‘Tendinopathy-Market Insights, Epidemiology, and Market Forecast–2030’ report deliver an in-depth understanding of the Tendinopathy, historical and forecasted epidemiology as well as the Tendinopathy market trends, market drivers, market barriers, SWOT analysis, reimbursement, and market access, and key companies involved such as MiMedx Group, R3 Stem Cell, Novartis Pharmaceuticals, University of Wisconsin-Madison, General Electric, Ipsen, Orthocell Limited.

Warm Autoimmune Hemolytic Anemia Market

DelveInsight’s ‘Warm Autoimmune Hemolytic Anemia – Market Insights, Epidemiology, and Market Forecast—2030’ report deliver an in-depth understanding of the wAIHA, historical and forecasted epidemiology as well as the market trends, market drivers, market barriers, and key companies involved such as Rigel Pharmaceuticals, Apellis Pharmaceuticals, Johnson & Johnson, Immunovant, Alexion Pharmaceuticals, Sanofi, Incyte Corporation, Annexon, and others.

Browse Through Our Blog Posts

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

For more insights, visit Pharma, Healthcare, and Biotech News


CONTACT: Contact Us Shruti Thakur info@delveinsight.com +1(919)321-6187 www.delveinsight.com


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting